Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...

By Shubham Batra (Reuters) -European shares slipped on Friday after a rally in the previous session spurred by the U.S.

The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...

Half a century of advancements in biomedical science paved the way for today's powerful weight-loss drugs like Ozempic -- so ...

Metro Mobility, a bike share startup, will offer electric bike rentals to low-income residents for only $1 a day as part of ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Novo Nordisk's deal with Korro is worth a total of $530 million in research and development (R&D) funding, milestone payments ...

NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product ...

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended an update to Novo Nordisk’s ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a ...